Brigatinib treated ALK positive lung squamous cell carcinoma after failed chemotherapy: A case report

The definitive efficacy of anaplastic lymphoma kinase (ALK) inhibitors in ALK positive lung squamous cell carcinoma (sqCC) patients remain unclear. Here, we report a case in which brigatinib had a therapeutic effect on ALK‐positive lung squamous cell carcinoma. The patient in this report was diagnos...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Shuluan, Zhang, Pei, Wang, Tianyu, Wang, Jie, Duan, Jianchun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2021
Materias:
Case Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8636200/
https://www.ncbi.nlm.nih.gov/pubmed/34647426
http://dx.doi.org/10.1111/1759-7714.14133
_version_ 1784608486222462976
author Li, Shuluan
Zhang, Pei
Wang, Tianyu
Wang, Jie
Duan, Jianchun
author_facet Li, Shuluan
Zhang, Pei
Wang, Tianyu
Wang, Jie
Duan, Jianchun
author_sort Li, Shuluan
collection PubMed
description The definitive efficacy of anaplastic lymphoma kinase (ALK) inhibitors in ALK positive lung squamous cell carcinoma (sqCC) patients remain unclear. Here, we report a case in which brigatinib had a therapeutic effect on ALK‐positive lung squamous cell carcinoma. The patient in this report was diagnosed with ALK‐positive lung squamous cell carcinoma with brain metastases, and received brigatinib after failure of first‐line chemotherapy. Response duration was approximately 11 months, with tolerable side effects. In conclusion, a good clinical effect was achieved in a patient with ALK positive lung squamous cell carcinoma who received treatment with an ALK inhibitor.
format Online
Article
Text
id pubmed-8636200
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher John Wiley & Sons Australia, Ltd
record_format MEDLINE/PubMed
spelling pubmed-86362002021-12-08 Brigatinib treated ALK positive lung squamous cell carcinoma after failed chemotherapy: A case report Li, Shuluan Zhang, Pei Wang, Tianyu Wang, Jie Duan, Jianchun Thorac Cancer Case Reports The definitive efficacy of anaplastic lymphoma kinase (ALK) inhibitors in ALK positive lung squamous cell carcinoma (sqCC) patients remain unclear. Here, we report a case in which brigatinib had a therapeutic effect on ALK‐positive lung squamous cell carcinoma. The patient in this report was diagnosed with ALK‐positive lung squamous cell carcinoma with brain metastases, and received brigatinib after failure of first‐line chemotherapy. Response duration was approximately 11 months, with tolerable side effects. In conclusion, a good clinical effect was achieved in a patient with ALK positive lung squamous cell carcinoma who received treatment with an ALK inhibitor. John Wiley & Sons Australia, Ltd 2021-10-13 2021-12 /pmc/articles/PMC8636200/ /pubmed/34647426 http://dx.doi.org/10.1111/1759-7714.14133 Text en © 2021 The Authors. Thoracic Cancer published by China Lung Oncology Group and John Wiley & Sons Australia, Ltd. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Case Reports
Li, Shuluan
Zhang, Pei
Wang, Tianyu
Wang, Jie
Duan, Jianchun
Brigatinib treated ALK positive lung squamous cell carcinoma after failed chemotherapy: A case report
title Brigatinib treated ALK positive lung squamous cell carcinoma after failed chemotherapy: A case report
title_full Brigatinib treated ALK positive lung squamous cell carcinoma after failed chemotherapy: A case report
title_fullStr Brigatinib treated ALK positive lung squamous cell carcinoma after failed chemotherapy: A case report
title_full_unstemmed Brigatinib treated ALK positive lung squamous cell carcinoma after failed chemotherapy: A case report
title_short Brigatinib treated ALK positive lung squamous cell carcinoma after failed chemotherapy: A case report
title_sort brigatinib treated alk positive lung squamous cell carcinoma after failed chemotherapy: a case report
topic Case Reports
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8636200/
https://www.ncbi.nlm.nih.gov/pubmed/34647426
http://dx.doi.org/10.1111/1759-7714.14133
work_keys_str_mv AT lishuluan brigatinibtreatedalkpositivelungsquamouscellcarcinomaafterfailedchemotherapyacasereport
AT zhangpei brigatinibtreatedalkpositivelungsquamouscellcarcinomaafterfailedchemotherapyacasereport
AT wangtianyu brigatinibtreatedalkpositivelungsquamouscellcarcinomaafterfailedchemotherapyacasereport
AT wangjie brigatinibtreatedalkpositivelungsquamouscellcarcinomaafterfailedchemotherapyacasereport
AT duanjianchun brigatinibtreatedalkpositivelungsquamouscellcarcinomaafterfailedchemotherapyacasereport

Ejemplares similares